» Articles » PMID: 38456787

The Prevalence and Radiologic Features of Renal Cancers Associated with , and Germline Mutations

Overview
Specialties Oncology
Radiology
Date 2024 Mar 8
PMID 38456787
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose To investigate the prevalence of , and mutations in an oncologic cohort and determine the prevalence, clinical features, and imaging features of renal cell carcinoma (RCC) associated with these mutations. Secondarily, to determine the prevalence of encountered benign renal lesions. Materials and Methods From 25 220 patients with cancer who prospectively underwent germline analysis with a panel of more than 70 cancer-predisposing genes from 2015 to 2021, patients with , or mutations were retrospectively identified. Clinical records were reviewed for patient age, sex, race/ethnicity, and renal cancer diagnosis. If RCC was present, baseline CT and MRI examinations were independently assessed by two radiologists. Summary statistics were used to summarize continuous and categorical variables by mutation. Results A total of 79 of 25 220 (0.31%) patients had a germline mutation: , 17 of 25 220 (0.07%); , 22 of 25 220 (0.09%); , 39 of 25 220 (0.15%); and , one of 25 220 (0.004%). Of these 79 patients, 18 (23%) were diagnosed with RCC (, four of 17 [24%]; , four of 22 [18%]; , nine of 39 [23%]; , one of one [100%]). Most hereditary RCCs demonstrated ill-defined margins, central nonenhancing area (cystic or necrotic), heterogeneous enhancement, and various other CT and MR radiologic features, overlapping with the radiologic appearance of nonhereditary RCCs. The prevalence of other benign solid renal lesions (other than complex cysts) in patients was up to 11%. Conclusion , and mutations were present in less than 1% of this oncologic cohort. Within the study sample size limits, imaging findings for hereditary RCC overlapped with those of nonhereditary RCC, and the prevalence of other associated benign solid renal lesions (other than complex cysts) was up to 11%. Familial Renal Cell Carcinoma, Birt-Hogg-Dubé Syndrome, Carcinoma, Renal Cell, Paragangliomas, Urinary, Kidney © RSNA, 2024.

Citing Articles

Hereditary renal mass syndromes: a pictorial review.

Yoon A, Tse J Abdom Radiol (NY). 2024; 50(2):794-806.

PMID: 39235599 DOI: 10.1007/s00261-024-04534-y.


Genetic Screening, Cancer Syndromes, and the Radiologist.

Choyke P Radiol Imaging Cancer. 2024; 6(2):e240045.

PMID: 38488500 PMC: 10988344. DOI: 10.1148/rycan.240045.

References
1.
Carlo M, Mukherjee S, Mandelker D, Vijai J, Kemel Y, Zhang L . Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. JAMA Oncol. 2018; 4(9):1228-1235. PMC: 6584283. DOI: 10.1001/jamaoncol.2018.1986. View

2.
Williamson S, Eble J, Amin M, Gupta N, Smith S, Sholl L . Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma. Mod Pathol. 2014; 28(1):80-94. DOI: 10.1038/modpathol.2014.86. View

3.
Maher E . Genetics of familial renal cancers. Nephron Exp Nephrol. 2010; 118(1):e21-6. DOI: 10.1159/000320892. View

4.
Casey R, Warren A, Martin J, Challis B, Rattenberry E, Whitworth J . Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review. J Clin Endocrinol Metab. 2017; 102(11):4013-4022. PMC: 5673270. DOI: 10.1210/jc.2017-00562. View

5.
Toro J, Wei M, Glenn G, Weinreich M, Toure O, Vocke C . BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. J Med Genet. 2008; 45(6):321-31. PMC: 2564862. DOI: 10.1136/jmg.2007.054304. View